Black Diamond Therapeutics, Inc. Income Statement
BDTX|2 years of annual SEC 10-K data (FY2019-FY2020)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$0
FY2020
Gross Profit
N/A
FY2020
Operating Income
-$70M
FY2020
Net Income
-$67M
FY2020
Black Diamond Therapeutics, Inc. reported $0 in revenue and $67M in net loss for FY2020.
Based on SEC 10-K filings.
Key Data Points
- Piotroski F-Score: 2/9 criteria passed
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -21.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| SG&A Expense | $21.4M | $7.6M |
| R&D Expense | $48.2M | $21.8M |
| Operating Income | -$69.6M | -$29.3M |
| Interest Expense | $1.0K | $0 |
| Income Tax | $0 | $0 |
| Net Income | -$67.3M | -$35.3M |
| EPS (Diluted) | -$16.99 | -$4.42 |
| Shares Outstanding | 2.2M | 2.2M |